Another-1 Immortalizes Street Art and Streetwear with ‘Drip-Lab’ - combining NFTs, PFPs and NFC Technology
20.7.2023 15:00:00 EEST | Business Wire | Press release
Another-1, the web3 luxury fashion platform, today announces the global launch of Drip-Lab – a multi-faceted phygital NFT project in collaboration with Como-based luxury technical fabric mill Olmetex, and renowned graffiti writer and artist Zoow24.
Drip-Lab launches with a mission to define the global intersection of art, graffiti, technology and streetwear, uniting a new and vibrant community of collectors and connoisseurs in the process. By launching a graffiti and street-culture inspired NFT collection, immortalizing Zoow24’s “The Wall” mural as an NFT, as well as linking the artist’s iconic illustrated characters to an NFC-enabled Olmetex fabricated windbreaker jacket, every aspect of the Drip-Lab project combines to ensure that historically ephemeral street art can be recorded, owned and flexed forever.
At the heart of this project are Zoow24’s five instantly recognisable ‘miniature behemoth’ monster character NFTs - REKT, EXTO, KULT, CRYMELON, and ROOT - which represent vices that can cause an artist to lose their way. The NFTs will be available with over 1,700 backgrounds, 183 monster traits, and 5,555 profile pictures (PFPs) variations as the Drip-Lab community grows.
In short, this unique blend of physical and digital (phygital) utility offers ‘Drip-Lab’ holders around the world the chance to flex a range of digital PFPs, physical products and murals, as well as augmented reality experiences that will be revealed with Another-1’s plans for future activations.
The ‘Drip-Lab’ Roadmap
The Pre-mint for ‘Drip-Lab’ is now live in anticipation of the sale on the Another-1 ADO Launchpad, allowing interested community members exclusive access to mint this project by linking their wallet ahead of the public offering.
Next week, on Wednesday, July 26th at 1pm EDT / 5pm UTC, presale for the project opens, and on July 27th at 1pm EDT / 5pm UTC the public sale will go live. An individual PFP will cost $150 USD each and to forge a customized jacket will cost $350 USD. After the drop, added benefits and utilities will be revealed as holders of these PFP project NFTs will benefit from a free airdrop of an NFT that immortalizes ‘The Wall’ art created by Zoow24 in Como. Adding the fashion and streetwear element, a highly anticipated aspect of this project is a limited edition windbreaker jacket that comes equipped with Near Field Communication (NFC) technology.
Designed by Olmetex, a world-renowned Italian mill setting the standard for fashion’s leading technical fabrics, these jackets showcase five captivating thermo-reactive dual-colorways and feature ZOOW24’s monsters on the inside lining for a customized finish.
Apart from making sure its wearer looks good in the streets, ‘The Writer’s Jacket’ will enable its owners’ to take advantage of Another-1’s ‘Flex-To-Earn’ module and get a 25% cash back airdrop in $AN1 tokens once the collection sales have been concluded, and the NFT redeem for the physical Jacket will be available later this year.
Speaking on the project, artist Zoow24 said, “Drip-Lab is a cautionary expose of what vices become when they spiral out of control. When you stop doing the drugs and the drugs do you. Habits are what make us human and how we choose to spend our time defines us as people.” “As a whole, this collaboration with Another-1 and Olmetex has created an opportunity for me to take my art, my characters and my creativity to a whole range of platforms and possibilities.”
Marco Staglianò, CEO of Another-1, added, “Our mission is to push the envelope and radically change the way art is produced and traded. By establishing the Drip-Lab project along with Olmetex and renowned artists such as Zoow24, we are proving that graffiti is a medium that can live on and be appreciated forever. This is a historical crossover of art, fashion, and groundbreaking technology and we’re excited for what’s still to come.”
“Working with a renowned fabric manufacturer like Olmetex, we also have the opportunity to tie physical fashion to this story of street and digital art. This is a first for the world and we’re excited to see how these passionate communities of street art and streetwear collectors will respond.”
Finally, Olmetex Managing Director, Beatrice Breschi had this to say: “Olmetex has decided to make the facade of its textile company available to graffiti artists, because it has always believed in the close union between fashion and art. This approach is a source of inspiration for our customers, which has always been part of our spirit and characteristics: elasticity, flexibility and constant openness to new ideas and challenges that the market offers. With these NFTs and the physical redemption of the waterproof jacket produced with its own fabrics, Olmetex sets itself the goal of making an art project tangible and fashionable.
“We’re excited to see our near-70 year old Mill involved in a web3 project that creates a new and important way to enjoy art and fashion. We have always been future-focused with our fabric innovation, and now we are taking this mindset to a collaboration that takes fashion, art and fabric into the next decade.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720752001/en/
Contact information
Bridget van Voorst
bridget@cw8-communications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
